| Filed On | Filing |
|---|---|
| 14 Jun 2021 |
8-K/A: Other Events
SELLAS Life Sciences Group, Inc. – Shareholder Update Call, June 3, 2021 |
| 28 Jan 2021 |
8-K/A: Financial Statements and Exhibits
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE SELLAS LIFE SCIENCES GROUP, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO SE... |
| 24 Oct 2018 |
8-K/A: Other Events
On October 23, 2018, the Court entered an order (i) granting in full the Company’s Motion for Judgment seeking dismissal of JGB’s Amended Complaint; (ii) denying JGB’s motion to dismiss the Company’s floor price breach of contract claim;... |
| 17 Oct 2018 |
8-K/A: Triggering Events That Accelerate a Financial Obligation; Other Events
Triggering Events that Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. |
| 05 Oct 2018 |
8-K/A: Triggering Events That Accelerate a Financial Obligation; Other Events
The disclosure set forth in Item 8.01 of this Current Report on Form 8-K/A to the extent required by this Item 2.04 is incorporated herein by reference. |
| 13 Apr 2018 |
8-K/A: Financial Statements and Exhibits
We were previously principal accountants for SELLAS Life Sciences Group Ltd and, under the date of September 22, 2017, we reported on the consolidated financial statements of SELLAS Life Sciences Group Ltd. as of and for the years ended ... |
| 02 Apr 2018 |
8-K/A: Changes in Registrant's Certifying Accountant
We were previously principal accountants for SELLAS Life Sciences Group Ltd and, under the date of September 22, 2017, we reported on the consolidated financial statements of SELLAS Life Sciences Group Ltd. as of and for the years ended ... |
| 11 Jan 2018 |
8-K/A: Completion of Acquisition or Disposition of Assets; Material Modification to Rights of Security Holders +6 more
On December 29, 2017 (the “Closing Date”), SELLAS Life Sciences Group, Inc., formerly known as Galena Biopharma, Inc. (the “Registrant”), completed its business combination with the Bermuda exempted company, Sellas Life Sciences Group Lt... |
| 26 Aug 2014 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
| 22 May 2012 |
8-K/A: Financial Statements and Exhibits
Galena Biopharma, Inc. (the “Company” or “Galena”) recently completed the partial spin-off of its wholly-owned subsidiary, RXi Pharmaceuticals Inc. (“RXi”) pursuant to the securities purchase agreement with RXi and two institutional inve... |
| 04 Apr 2012 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined statement of expenses combines the historical statement of expenses of Galena Biopharma, Inc. (formerly known as RXi Pharmaceuticals Corporation) (“Galena”)) and the historical stateme... |
| 10 Jun 2011 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined financial information combines (i) the historical balance sheets of RXi Pharmaceuticals Corporation (“RXi”) and Apthera, Inc. (“Apthera”) as of March 31, 2011, giving pro forma effect ... |
| 04 May 2011 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined financial information combines (i) the historical balance sheets of RXi Pharmaceuticals Corporation (“RXi”) and Apthera, Inc. (“Apthera”) as of December 31, 2010, giving pro forma effe... |
| 14 Apr 2011 |
8-K/A: Financial Statements and Exhibits
We have audited the accompanying balance sheets of Apthera, Inc. (“Company”) as of December 31, 2010 and 2009, and the related statements of operations, changes in stockholders’ deficit and cash flows for the years ended December 31, 201... |
Loading...